Stockreport

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results

Aligos Therapeutics, Inc. - Common stock  (ALGS) 
PDF SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on im [Read more]